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Abstract
Background: Worms may protect against allergy. Early-life worm exposure may be
critical, but this has not been fully investigated.
Objectives: To investigate whether worms in pregnancy and in early childhood are
associated with childhood eczema incidence.
Methods: The Entebbe Mother and Baby Study, an anthelminthic treatment trial,
enrolled pregnant women between 2003 and 2005 inUganda.Mothers were investigated
for worms during pregnancy and children annually. Eczemawas doctor-diagnosed from
birth to age five years. A planned observational analysis was conducted within the trial
cohort to investigate associations between worms and eczema.
Results: Data for 2345 live-born children were analysed. Hookworm was the most
prevalent maternal worm (45%). Childhood worms were less prevalent. Eczema
incidence was 4.68/100 person-years. Maternal hookworm was associated with
reduced eczema incidence [adjusted hazard ratio (95% confidence interval), p-value:
0.71(0.51–0.99), 0.04] and modified effects of known risk factors for eczema:
Dermatophagoides-specific IgE in children was positively associated with eczema
incidence if the mother had no hookworm [2.72(1.11–6.63), 0.03], but not if the mother
had hookworm [0.41(0.10–1.69), 0.22], interaction p-value = 0.03. Similar interactions
were seen for maternal history of eczema {[2.87(1.31–6.27, 0.008) vs. [0.73(0.23–2.30),
0.60], interaction p-value = 0.05}, female gender {[1.82(1.22–2.73), 0.004 vs. [0.96
(0.60–1.53), 0.87], interaction p-value = 0.04} and allergen-specific IgE. Childhood
Trichuris trichiura and hookworm were inversely associated with eczema.
Conclusions: Maternal hookworm modifies effects of known risk factors for eczema.
Mechanisms by which early-life worm exposures influence allergy need investigation.
Worms or worm products, and intervention during pregnancy have potential for
primary prevention of allergy.
Allergy is a global problem affecting approximately 20% of the
world’s population (1) and is on the increase in developing
countries, but the causes of this increase are unknown (2).
Environmental factors and gene–environment interactions
have an important role in the aetiology of allergy (3).
Atopy, measured by increased allergen-specific IgE or
positive skin prick responses to allergens, is a strong risk factor
for allergy in developed countries but reportedly less so in
developing countries (4–6). The reasons for this discrepancy are
not known, but there is a suggestion that chronic immune-
modulating infections such as worms, which are prevalent in
developing countries, could play a role (7). Several observational
studies have investigated associations between worms and
allergy [reviewed by Leonardi-Bee et al. (8) and Flohr et al.
(9)]. Results from these studies are inconsistent: some show an
inverse association, others a positive association and some no
association. There is evidence that prenatal exposure to worms
influences later responses to childhood worm infections (10) and
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possibly to unrelated antigens such as BCG vaccine (11). In this
analysis, we investigated whether exposure to worms during
pregnancy and in early childhood was associated with eczema
incidence in early childhood.
Methods
Study setting
Entebbe Mother and Baby Study (EMaBS) was a trial among
pregnant women and their offspring residing in peri-urban,
fishing and rural communities beside Lake victoria, Uganda.
Details of the trial design are reported elsewhere (12). In
summary, EMaBS was a randomized, double-blinded, placebo-
controlled trial of anthelminthic treatment in pregnancy using
single-dose albendazole (400 mg) or placebo and praziquantel
(40 mg/kg) or placebo in a 2 9 2 factorial design. At age
fifteen months, the children resulting from these pregnancies
were randomized to receive either albendazole or placebo
quarterly until age five years (12).
The study was approved by the Uganda Virus Research
Institute Science and Ethics Committee, the Uganda National
Council for Science and Technology, and the London School
of Hygiene and Tropical Medicine ethics committee.
Specific objective
The objective of this analysis was to investigate whether worm
infections in pregnancy and in early childhood are associated
with reduced eczema incidence in the first five years of life.
Study enrolment and follow-up
EMaBS eligibility criteria have been reported elsewhere (12).
Eligible pregnant women provided written informed consent
prior to enrolment and provided stool and blood samples at
enrolment and delivery. At enrolment, a questionnaire was
completed, and women underwent testing for asymptomatic
malaria and for HIV. Six weeks after delivery, all women
received anthelminthic treatment with both albendazole and
praziquantel. They were encouraged to bring the children to
the study clinic for routine immunisations and for the
treatment of illnesses, all free of charge.
Children were routinely seen annually, as close to their
birthday as possible, to provide stool and blood samples. Worm
infections detected at annual visits were treated. Children seen at
age three betweenNovember 2007 andMarch 2009were selected
for skin prick tests and allergen-specific IgE testing.
Skin prick tests and allergen-specific IgE
We conducted skin prick testing (SPT) according to standard
procedure (13) using Blomia tropicalis, Dermatophagoides mix,
cow’s milk and egg white, with histamine and saline controls
(ALK Abello, Hoersholm, Denmark). A diameter of ≥3 mm
was considered positive.
Allergen-specific IgE testing was performed for children who
underwent SPT at three years by ELISA, as previously
described (14), using Dermatophagoides mix (Dermatophago-
ides farina and Dermatophagoides pteronyssinus) and German
cockroach (Blattella germanica) (Greer Labs, Lenoir, NC,
USA). Positive sera standardized using the Immunocap Assay
System (Phadia, Uppsala, Sweden) were used to standardize
the ELISA assay.
Other laboratory procedures
Stool samples were analysed by the Kato-Katz (15) method.
Two slides were examined for each sample, read within 30 min
for hookworm and the following day for the other worms
including Schistosoma mansoni, Trichuris trichiura and Ascaris
lumbricoides. We used the charcoal culture method (16) for
Strongyloides stercoralis, thick blood smears for malaria
infection and the modified Knott’s method for Mansonella
perstans and other microfilariae (17).
Statistical methods
Data were collected on pre-coded case report forms and
analysed using STATA version 10 (Stata Corp., College Station,
TX, USA). The sample size of 2500 pregnant women for the
EMaBS trial was planned for infectious disease end-points for
the trial interventions (12). Assuming eczema incidence of 5 per
100 person-years, this observational analysis would have over
80% power to detect exposures with a rate ratio of 1.30 or
higher, at 5% significance level. This observational analysis
was a planned secondary analysis for the trial cohort.
Outcomes and exposures
The primary outcome for this analysis was doctor-diagnosed
eczema, defined as a recurrent itchy rash, with either wet
weeping skin or dry scaly skin and with a typical distribution
(18). Eczema was either a presenting complaint or an incidental
finding during routine or other illness visits.
Worm infections were the primary exposures of interest.
Maternal socio-economic status, education, area of residence
and history of allergy were considered as potential confounders
for the association between worms and eczema and as
exposures of interest in their own right. In addition, children’s
birth order, birth weight and childhood illnesses were consid-
ered as potential confounders for the association between
childhood worms and eczema, as well as exposures. Children’s
atopic status (SPT and allergen-specific IgE) was considered as
exposures.
For atopy and for other factors that were positively
associated with eczema, maternal hookworm was investigated
as a potential effect modifier. Effect modification by the trial
interventions was also investigated.
Recoding of variables
Principal component analysis was used to identify dominant
variables (household items owned, building materials and
number of rooms) to create a score that was regrouped as
lower vs. higher socio-economic status (19). Area of residence
was divided into zones based on topography and the grouping
of settlements, which followed geo-referencing of participant’s
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addresses using hand-held global-positioning system receivers
(Garmin eTrex) (20). A World Health Organisation (WHO)
infection intensity classification was used for hookworm (21).
For maternal asymptomatic malaria, results at enrolment and
delivery were combined to generate a binary variable for
malaria during pregnancy.
For childhood illnesses, numbers of episodes of malaria,
diarrhoea, lower and upper respiratory tract infection were
analysed as continuous variables. Due to the low prevalence of
childhood worm infections, data from one to five years were
combined into a single binary variable (ever infected or never
infected) for each type of worm infection. We used the
standard cut-off point (0.35 kUA/l) for allergen-specific IgE
to categorize children as atopic or non-atopic.
Regression analysis
We used Cox regression to assess crude and adjusted associa-
tions between exposures and eczema incidence, with robust
standard errors to allow for clustering of events within each
child. TheWald test was used to test for effect modification. For
each child, time at risk began at birth and ended either at five
years of age, loss to follow-up or death. Factors listed above as
potential confounders were included in multivariable models,
with the exception of those with substantial missing data and
those whose inclusion had no impact on the hazard ratios for
other exposures. Analyses for child’s gender and atopy were not
adjusted as no potential confounders were identified.
Results
Participants’ profile
Between April 2003 and November 2005, EMaBS enrolled
2507 pregnant women resulting in 2345 recorded live births.
Follow-up of children started from birth of the first child in
April 2003 and finished in April 2011, when the last child
reached five years. Follow-up time for 116 (5.0%) and 594
(25.3%) of the 2345 live-born children was censored at death or
loss to follow-up, respectively, leaving 1635 (69.7%) still in
follow-up at age five years (22). The mean number of routine or
illness clinic visits per child was 14 (range 0–63).
Mothers were mostly of low education status, and worm
prevalence was high (68% infected with at least one worm
species).
Eczema incidence was 10.4/100 person-years of follow-up
(pyrs) in infancy (14) and4.68/100pyrs in the first five years of life.
Maternal factors associated with childhood eczema
Associations between maternal factors and eczema incidence
are shown in Table 1. Children from rural areas had signifi-
cantly less eczema compared with children from urban areas.
Maternal history of eczema was strongly associated with
childhood eczema. There was a strong association between
maternal albendazole and childhood eczema as previously
reported (14).
Maternal hookworm was inversely associated with eczema
incidence, and this association was strongest among those with
heavier infections (Table 1). In adjusted analyses, maternal
infections with other worm species were not associated with
childhood eczema. Maternal asymptomatic malaria infection
during pregnancy had a strong inverse association with
childhood eczema.
Childhood factors associated with childhood eczema
As presented in Table 2, neither child’s birth order nor birth
weight was associated with childhood eczema. Female children
had a higher eczema incidence. There was an inverse associ-
ation between the number of malaria episodes and eczema, but
not for diarrhoea, lower or upper respiratory infections. The
prevalence of worm infections in the first five years was
relatively low. Childhood T. trichiura and hookworm were
inversely associated with eczema. The remaining worm infec-
tions showed either a weak inverse association or no associ-
ation with eczema.
Three-year-old children with a positive skin prick test (to
any of the four allergens) had a higher incidence of eczema.
Positive allergen-specific IgE responses to Dermatophagoides
mix, and German cockroach allergens showed no overall
association with eczema.
Effect modification of maternal hookworm on risk factors
associated with eczema
To understand why the association between atopy and allergy is
weak in developing countries, we examined the role of worms as
potential effect modifiers. We investigated whether hookworm,
the most prevalent maternal worm, modified the effects of atopy
and other risk factors positively associated with eczema in this
analysis (Table 3). We found a strong positive association
between maternal history of eczema and childhood eczema
among children whose mothers had no hookworm infection
during pregnancy, but not among children whose mothers were
infected with hookworm (interaction p-value 0.05), despite
similarities in the prevalence of history of eczema amongmothers
with or without hookworm. Similar trends towards effect
modification by hookworm were observed for associations
between eczema and maternal albendazole treatment during
pregnancyandbetweeneczemaand skinprick test responses in the
children, but these were not statistically significant. Female
children had a higher eczema incidence if their mothers had no
hookworm, but not if they had hookworm (interaction p-value
0.04). Dermatophagoides mix-specific IgE showed a strong
positive association with eczema among the children whose
mothers had no hookworm during pregnancy, but not among
children whose mothers had hookworm (interaction p-value
0.03). Cockroach-specific IgE had a weak positive association
with eczema among children whose mothers had no hookworm,
butaweak inverse association among childrenwhosemothers had
hookworm (interaction p-value 0.01). Less prevalent maternal
worm infections showed a similar trend to that of hookworm but
power to detect effect modification was low (results not shown).
Effect of trial anthelminthic drugs on the association between
worms and eczema
We found a strong inverse association between maternal
hookworm and eczema if the mother received albendazole
[aHR (95% CI) 0.57 (0.37–0.90)] that was not present if the
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mother received albendazole placebo [0.99 (0.62–1.60)],
although this interaction was not significant (p-value 0.13).
The association between childhood hookworm (and T. trich-
iura) and eczema was not influenced by the three-monthly
albendazole/placebo that the children were randomized to
receive.
Discussion
This is the first study to show that maternal hookworm infection
is inversely associatedwith eczema incidence andmodifies effects
of known risk factors for childhood eczema such as mother’s
history of eczema, child’s gender and atopic status.
Table 1 Maternal factors and their association with childhood eczema in the first five years of life
Maternal factor
Number of
children in
each
category (%)
No of
eczema
events
Person-years
at risk (9100)
Rate (per
100 pyrs) Crude HR (95% CI) aHR*(95% CI) p-value
Education†
None/primary 1278 (55) 232 51.65 4.49 1 1 0.85
Post-primary 1063 (45) 220 44.63 4.93 1.11 (0.84–1.54) 0.97 (0.70–1.35)
Household socio-economic status‡
Lower status 1053 (46) 164 42.78 3.83 1 1 0.08
Higher status 1248 (54) 274 51.89 5.28 1.39 (0.99–1.96) 1.36 (0.96–1.92)
Area of residence§
Entebbe, town 950 (41) 251 38.74 6.48 1 1 0.002
Kiggungu, fishing village 261 (11) 18 11.25 1.60 0.25 (0.14–0.43) 0.27 (0.15–0.46)
Manyago and Kabale, peri-urban 651 (28) 131 26.89 4.87 0.75 (0.53–1.07) 0.76 (0.52–1.10)
Katabi, rural 451 (20) 48 18.48 2.60 0.40 (0.25–0.66) 0.42 (0.25–0.68)
Regular cigarette smoking by adult in house¶
No 1429 (81) 320 66.18 4.83 1 1 0.56
Yes 330 (19) 81 14.98 5.41 1.11 (0.64–1.92) 1.17 (0.69–1.99)
Maternal history of asthmak
None 1706 (97) 382 78.66 4.86 1 1 0.26
Yes 60 (3) 19 2.84 6.70 1.40 (0.73–2.70) 1.44 (0.76–2.74)
Maternal history of eczema**
None 1710 (97) 374 78.94 4.74 1 1 0.02
Yes 56 (3) 27 2.55 10.59 2.24 (1.12–4.47) 2.28 (1.14–4.53)
Maternal albendazole trial arm during pregnancy
Placebo arm 1175 (50) 175 48.21 3.63 1 – 0.005
Albendazole arm 1170 (50) 277 48.26 5.74 1.58 (1.15–2.17)
Maternal worm infections during pregnancy
1. Hookworm††: None 1311 (56) 298 54.34 5.48 1 1 0.04
Yes 1025 (44) 151 41.78 3.61 0.65 (0.48–0.90) 0.71 (0.51–0.99)
2. M. perstans‡‡: None 1841 (79) 389 75.85 5.13 1 1 0.10
Yes 496 (21) 63 20.32 3.10 0.60 (0.39–0.92) 0.70 (0.45–1.07)
3. S. mansoni††: None 1915 (82) 381 78.56 4.85 1 1 0.51
Yes 421 (18) 68 17.55 3.87 0.80 (0.55–1.15) 0.88 (0.61–1.28)
4. S. stercoralis§§: None 2041 (88) 380 84.03 4.52 1 1 0.33
Yes 283 (12) 65 11.60 5.60 1.23 (0.77–1.95) 1.27 (0.78–2.06)
5. T. trichiura††: None 2130 (91) 422 87.81 4.81 1 1 0.59
Yes 206 (9) 27 8.30 3.25 0.67 (0.24–1.86) 0.73 (0.23–2.33)
6. A. lumbricoides††: No 2282 (98) 466 93.87 4.75 1 1 0.08
Yes 54 (2) 3 2.25 1.33 0.28 (0.09–0.87) 0.37 (0.12–1.14)
Hookworm category††
None 1311 (56) 298 54.34 5.48 1 1 0.03
Mild 872 (37) 134 35.70 3.75 0.68 (0.49–0.95) 0.74 (0.53–1.04)
Mod-severe 153 (7) 17 6.08 2.79 0.51 (0.27–0.96) 0.56 (0.30–1.07)
Maternal asymptomatic malaria during pregnancy¶¶
None 2037 (88) 414 84.23 4.91 1 1 0.03
Yes 266 (12) 34 10.64 3.20 0.65 (0.41–1.02) 0.59 (0.37–0.95)
Pyrs, person years; CI, confidence interval; HR, hazard ratio; aHR, adjusted hazard ratio.
*Adjusted for maternal education, area of residence and household socio-economic status.
No of missing variables: † = 4, ‡ = 44, § = 32, ¶ = 586, k = 579, ** = 579, †† = 9, ‡‡ = 8, §§ = 21, ¶¶ = 42.
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Table 2 Childhood factors associated with eczema in the first five years of life
Childhood factor
Number of
children in
each
category (%)
No of
eczema
events
Person-years
at risk (9100)
Rate
(per 100 pyrs)
Crude HR
(95% CI) aHR† (95% CI) p-value*
Child’s birth order
First born 622 (27) 108 24.25 4.45 1 1 0.06
2nd–4th born 1342 (57) 257 55.91 4.60 1.05 (0.72–1.53) 1.07 (0.73–1.58)
5th born or more 381 (16) 87 16.31 5.33 1.22 (0.73–2.05) 1.37 (0.82–2.27)
Child’s birth weight¶
Normal 1719 (90) 368 71.70 5.13 1 1 0.48
Low (≤2.5 kg) 187 (10) 31 7.50 4.13 0.81 (0.43–1.51) 0.79 (0.41–1.51)
Child’s sexk
Male 1208 (52) 193 49.75 3.88 1 – 0.03
Female 1135 (48) 259 46.72 5.54 1.43 (1.04–1.97) –
Common childhood infections diagnosed prospectively (0–5 yr)
1. Malaria
Mean (range) of
episodes: 1.4 (0–16)
– – – 0.94 (0.88–1.00) 0.88 (0.83–0.94) <0.0001
2. Diarrhoea
Mean (range) of
episodes: 2.6 (0–22)
– – – 1.10 (1.05–1.16) 1.02 (0.93–1.10) 0.71
3. Lower respiratory infections
Mean (range) of
episodes: 0.4 (0–9)
– – – 1.25 (1.11–1.41) 1.10 (0.96–1.26) 0.18
4. Upper respiratory infections
Mean (range) of
episodes: 11 (0–58)
– – – 1.04 (1.03–1.06) 1.00 (0.95–1.04) 0.92
Childhood worm infections‡ (assessed annually from 1 to 5 yr)
1. T. trichiura (810):None 643 (79) 179 32.08 5.58 1 1 0.002
Yes 167 (21) 16 8.13 1.97 0.35 (0.18–0.66) 0.35 (0.18–0.67)
2. A. lumbricoides
(765): None
680 (89) 180 33.93 5.30 1 1 0.22
Yes 85 (11) 12 4.11 2.92 0.54 (0.28–1.06) 0.64 (0.32–1.30)
3. S. mansoni (756): None 700 (93) 177 34.93 5.07 1 1 0.45
Yes 56 (7) 14 2.70 5.19 1.00 (0.34–2.97) 1.55 (0.50–4.81)
4. Hookworm (747): None 705 (94) 185 35.18 5.26 1 1 0.05
Yes 42 (6) 4 1.99 2.01 0.37 (0.14–0.98) 0.33 (0.11–1.02)
5. M. perstans (864): None 839 (97) 206 41.87 4.92 1 1 0.28
Yes 25 (3) 9 1.14 7.86 1.54 (0.66–3.59) 1.60 (0.68–3.77)
Child’s atopic status (assessed at 3 yr)§
Skin prick responses (569)
Negative 464 (82) 67 22.71 2.95 1 – <0.0001
Positive 105 (18) 49 5.08 9.65 3.26 (1.84–5.80) –
Dermatophagoides-specific IgE (540)
Non-atopic 478 (89) 93 23.34 3.98 1 – 0.21
Atopic 62 (11) 20 3.02 6.62 1.66 (0.75–3.69) –
Cockroach-specific IgE (540)
Non-atopic 448 (83) 91 21.90 4.15 1 – 0.67
Atopic 92 (17) 22 4.46 4.94 1.18 (0.55–2.55) –
Pyrs, person years; CI, confidence interval; HR, hazard ratio; aHR, adjusted hazard ratio.
*For categorical variables, this is the p-value for the test of trend.
†Adjustedformaternaleducation, areaof residenceandhouseholdsocio-economicstatus;childhood illnesseswereadditionallyadjustedfor the total
number of clinic visits a childmade during the study period. Breastfeeding was not adjusted for as 98%of the children in this studywere breastfed.
‡Children with data on worm infections at all five annual visits were included for this analysis.
§Three-year-old children seen between November 2007 and March 2009 were selected for skin prick tests (4 allergens) and allergen-specific IgE
testing.
No of missing variables: ¶ = 430, k = 2.
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We also found that early childhood hookworm and
T. trichiura, although of low prevalence, were associated with
a reduced incidence of eczema. It is important to note that
most eczema episodes occurred in infancy, before most
children acquired any worm infections, suggesting that the
observed inverse association is not causal but may be due to
other environmental exposures or to a genetic predisposition –
such that children predisposed to eczema might be less
susceptible to worm infections.
The study had a number of limitations. First, worm infections
were determined by the Kato Katz method using a single stool
sample, which is relatively insensitive (23). Secondly, confound-
ing is an inherent flaw of cohort studies, and it is possible that
there are unmeasured confounders. Thirdly, clinicians were not
blinded to the worm status of the participants, which may have
led to observer bias. However, this is unlikely to have affected
the antibody results as immunology technicians were unaware of
the worm status of the participants. Lastly, we tested only a
sample of children for atopy. This reduced power of the study,
particularly for interaction analyses.
Our findings are generalisable to other communities in
developing countries with high prevalence but low intensity of
hookworm infections.
Other studies have investigated possible modifying effects of
worms on the association between atopy and allergy and
obtained results similar to ours. A case–control study in
Ecuador found that the association between atopy and wheeze
was stronger among uninfected children compared with those
with geohelminths (24). A study among Cuban children found
a strong positive association between atopy and physician-
diagnosed asthma among children without Toxocara antibod-
ies, but a weak association among those with Toxocara
antibodies (25). This evidence suggests that worm infections
may, at least in part, explain why atopy is weakly associated
with clinical allergy in developing countries, in contrast to the
strong associations reported in developed countries.
The finding of an inverse association between malaria and
eczema was unexpected but was consistent for asymptomatic
malaria in pregnancy and for clinical malaria illnesses in early
childhood. Malaria is a potent immune modulator which can
influence the response to unrelated antigens (26).
The observation that children from rural areas were at
reduced risk of eczema compared with their counterparts from
urban areas has also been observed in other developing
countries (27, 28). This difference remained even after adjust-
ing for worms and potential confounders. What is intriguing is
that these urban/rural areas are located within the same
district, a relatively small geographical area. Perhaps, multiple
infections, or exposure to farm animals or other aspects of
rural life, whose effect was not measured in this analysis, might
explain these urban/rural differences.
This study has important implications for future research.
First, there is urgent need to understand the underlying
immune mechanisms by which hookworm could modify the
effects of known risk factors for eczema. Such studies may take
the form of clinical trials of worms for therapy or worm
products. Indeed, early phase clinical trials, using iatrogenic
hookworm, have been initiated in the United Kingdom (29,
30). With careful attention to design, studies in developing
countries can be useful as the effects of interventions for worm
control on allergy are explored. Secondly, pregnancy and early
childhood provide a window of opportunity during which
interventions for the primary prevention of allergy could be
targeted.
Conclusion
We have demonstrated that prenatal hookworm exposure
modifies the effects of known risk factors for childhood eczema
and that early childhood worms are associated with reduced
eczema incidence. More research is needed to understand
possible underlying immune mechanisms and to explore the
therapeutic potential of worms or their products, particularly
during pregnancy or early childhood, in the primary preven-
tion of allergy.
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